CN110521872A - 一种赖氨酸膏及其在猫咪营养摄取中的应用 - Google Patents
一种赖氨酸膏及其在猫咪营养摄取中的应用 Download PDFInfo
- Publication number
- CN110521872A CN110521872A CN201910903966.9A CN201910903966A CN110521872A CN 110521872 A CN110521872 A CN 110521872A CN 201910903966 A CN201910903966 A CN 201910903966A CN 110521872 A CN110521872 A CN 110521872A
- Authority
- CN
- China
- Prior art keywords
- parts
- lysine
- cat
- cream
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282326 Felis catus Species 0.000 title claims abstract description 79
- 239000004472 Lysine Substances 0.000 title claims abstract description 56
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000006071 cream Substances 0.000 title claims abstract description 43
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 11
- 230000035764 nutrition Effects 0.000 title claims abstract description 9
- 229920000159 gelatin Polymers 0.000 claims abstract description 13
- 235000019322 gelatine Nutrition 0.000 claims abstract description 13
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 10
- 239000003765 sweetening agent Substances 0.000 claims abstract description 10
- 229940088594 vitamin Drugs 0.000 claims abstract description 10
- 229930003231 vitamin Natural products 0.000 claims abstract description 10
- 235000013343 vitamin Nutrition 0.000 claims abstract description 10
- 239000011782 vitamin Substances 0.000 claims abstract description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 9
- 241000287828 Gallus gallus Species 0.000 claims abstract description 8
- 239000001828 Gelatine Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000010775 animal oil Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 108010028690 Fish Proteins Proteins 0.000 claims abstract description 6
- 108010010803 Gelatin Proteins 0.000 claims abstract description 6
- 229930006000 Sucrose Natural products 0.000 claims abstract description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 6
- 239000005720 sucrose Substances 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 235000020247 cow milk Nutrition 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000007062 hydrolysis Effects 0.000 claims abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 11
- 230000037213 diet Effects 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019411 steviol glycoside Nutrition 0.000 claims description 3
- 229930182488 steviol glycoside Natural products 0.000 claims description 3
- 150000008144 steviol glycosides Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000019629 palatability Nutrition 0.000 abstract description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 43
- 235000018977 lysine Nutrition 0.000 description 41
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 235000010374 vitamin B1 Nutrition 0.000 description 3
- 239000011691 vitamin B1 Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- BOKGTLAJQHTOKE-UHFFFAOYSA-N 1,5-dihydroxynaphthalene Chemical compound C1=CC=C2C(O)=CC=CC2=C1O BOKGTLAJQHTOKE-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010419 pet care Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
Abstract
本发明涉及宠物营养膏剂的技术领域,具体涉及一种赖氨酸膏,其由包括如下重量份的原料配制而成:明胶1‑5份、羟甲基纤维素钠10‑20份、蔗糖90‑110份、牛磺酸1‑10份、全脂牛奶粉25‑40份、水解鱼蛋白粉20‑40份、骨胶20‑40份、维生素1.25‑5.95份、甜味剂70‑90份、鸡水解膏60‑130份、动物油100‑120份、L‑赖氨酸盐酸盐250‑280份和水220‑230份;本发明还公开了该赖氨酸膏在猫咪营养摄取中的应用,将赖氨酸膏用于喂食猫咪,本发明的赖氨酸浓度高,对猫咪的适口性好,可以为猫咪提供赖氨酸和其他营养物质,具有较好的治疗和预防猫鼻支的作用。
Description
技术领域
本发明涉及宠物营养膏剂的技术领域,具体涉及一种赖氨酸膏及其在猫咪营养摄取中的应用。
背景技术
随着生活水平的提高,人们对待宠物越来越精心。作为宠物主人和所有从事宠物行业的人来说,对宠物的营养摄取和健康备受关注。目前,市场上已经出现众多的宠物保健品,用于补充宠物生长所需的维生素和多种营养成分。其中,猫咪的营养品有维生素片、高钙片、微量元素片、膏剂等,而膏剂则以其易吸收、适口性好、服用方便、便于携带等优点深受广大宠物主人的喜爱。
研究表明,80%的猫咪都携带有猫疱疹病毒,只是猫咪平时身体健康时,病毒无法“入侵”,一旦猫咪身体状况不佳时,病毒就可能趁机而入。赖氨酸对于猫疱疹病毒有很好的预防效果,因此,在猫粮中或是在日常饲喂时,适当给猫咪补充赖氨酸非常重要。目前,已出现多种赖氨酸膏,旨在为猫咪补充能提高机体免疫力的赖氨酸,膏剂中含有多种维生素、牛磺酸等,不仅能提高猫咪的免疫力,还可补充各种维生素和营养成分。
但是,由于猫咪独特的生理习性,它们一次的摄食量很少且对苦味很敏感,为了达到赖氨酸的起效剂量,需提高产品中赖氨酸的含量,但赖氨酸带有浓重的苦涩味,因此在提高产品中赖氨酸浓度的同时会使产品的口味变苦,从而使其口感变差,苦涩味会导致猫咪拒绝进食含有赖氨酸的产品。
发明内容
本发明的第一个目的在于提供一种赖氨酸膏,在提高产品赖氨酸浓度的同时,还能大大提高产品的适口性。
本发明的第一个目的通过以下技术方案来实现:
一种赖氨酸膏,其由包括如下重量份的原料配制而成:明胶1-5份、羟甲基纤维素钠10-20份、蔗糖90-110份、牛磺酸1-10份、全脂牛奶粉25-40份、水解鱼蛋白粉20-40份、骨胶20-40份、维生素1.25-5.95份、甜味剂70-90份、鸡水解膏60-130份、动物油100-120份、L-赖氨酸盐酸盐250-280份和水220-230份。
通过采用上述技术方案,骨胶,动物胶的主要成分是明胶肽蛋白质,其纯度低的一种称骨胶,骨胶是淡黄色粉末。水解鱼蛋白粉中的粗蛋白含量不低于50%,是一种高蛋白、低脂肪的蛋白水解制品;该产品含有较多的多肽和氨基酸,可纠正机体长期缺乏蛋白质而造成的营养不良现象,并能纠正消化道紊乱,改善消化功能。L-赖氨酸盐酸盐,即赖氨酸。
作为优选,其由包括如下重量份的原料配制而成:明胶2-4份、羟甲基纤维素钠13-17份、蔗糖95-105份、全脂牛奶粉30-35份、牛磺酸3-8份、水解鱼蛋白粉25-35份、骨胶25-35份、维生素2.41-4.56份、甜味剂75-85份、鸡水解膏90-110份、动物油105-115份、L-赖氨酸盐酸盐260-270份和水221-227份。
作为优选,所述维生素包括维生素E 1-5份、维生素A 0.1-0.5份、维生素B1 0.05-0.15份、维生素B2 0.05-0.15份和维生素B6 0.05-0.15份。
通过采用上述技术方案,维生素E具有延缓衰老、减少细胞消耗量、抗氧化保护机体细胞免受自由基的毒害等作用。维生素A有促进生长、繁殖,维持骨骼、上皮组织、视力和粘膜上皮正常分泌等多种生理功能,有阻止癌前期病变的作用。维生素B1能增进食欲,维持神经正常活动,改善精神状况,维持神经组织、肌肉、心脏活动的正常。维生素B2主要参与的生化反应有呼吸链能量产生,氨基酸、脂类氧化,嘌呤碱转化为尿酸,芳香族化合物的羟化,蛋白质与某些激素的合成,铁的转运、储存及动员,参与叶酸、吡多醛、尼克酸的代谢等。维生素B6参与蛋白质合成与分解代谢,参与所有氨基酸代谢,如与血红素的代谢有关,与色氨酸合成烟酸有关;参与糖异生、UFA代谢,与糖原、神经鞘磷脂和类固醇的代谢有关;参与某些神经介质(5-羟色胺、牛磺酸、多巴胺、去甲肾上腺素和γ-氨基丁酸)合成;参与核酸和DNA合成,缺乏会损害DNA的合成,这个过程对维持适宜的免疫功能是非常重要的;维生素B6与维生素B2的关系十分密切,维生素B6缺乏常伴有维生素B2症状;参与同型半胱氨酸向蛋氨酸的转化,具有降低慢性病的作用,轻度高同型半胱氨酸血症被认为是血管疾病的一种可能危险因素,维生素B6的干预可降低血浆同型半胱氨酸含量。在维生素B1和维生素B2存在时,会增加维生素B6的功能。
作为优选,所述动物油包括鸡油和鱼油。
通过采用上述技术方案,鸡油富含蛋白质和脂肪。鱼油富含二十碳五烯酸(EPA)、二十二碳六烯酸(DHA,俗称脑黄金)、α-亚麻酸等多种n-3系多不饱和脂肪酸(n-3PUFA),具有调节血脂等作用。
作为优选,所述甜味剂包括甜菊糖苷、海藻糖、甘氨酸、L-丙氨酸、丝氨酸中的一种或多种。
通过采用上述技术方案,甜菊糖苷,白色粉末,是天然低热量的甜味剂。甜菊糖的热值仅为蔗糖的1/300,摄入后不被吸收,不产生热量,更健康。海藻糖,是一种安全、可靠的天然糖类;甘氨酸、L-丙氨酸、丝氨酸则为具有甜味的氨基酸,在补充营养的同时可以起到甜味增效的作用。
本发明的第二个目的是提供一种上述赖氨酸膏在猫咪营养摄取中的应用,将所述赖氨酸膏掺入猫咪日常饮食中,或直接喂食猫咪,为猫咪补充赖氨酸。
通过采用上述技术方案,通过食用本发明高浓度的赖氨酸膏,为猫咪提供赖氨酸及其他营养成分,提高猫咪的免疫力,达到预防猫鼻支的效果。
综上所述,本发明具有如下有益效果:
本发明在保证赖氨酸膏适口性的基础上,提高了赖氨酸的浓度,使膏剂中赖氨酸的浓度高达24%以上。
具体实施方式
实施例1-7
实施例1-7的赖氨酸膏,其各原料含量如表1所示。
表1赖氨酸膏的原料含量(单位/g)
对比例1
对比例1与实施例3的区别在于原料中无甜味剂,其余与实施例3中均相同。
对比例2
对比例2与实施例1的区别在于原料中无甜味剂,其余与实施例1中均相同。用法用量本发明的赖氨酸膏,一管净重为120g,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g。
选取80只患有猫鼻支的猫咪,猫咪的品种不限定,均分为A1组、B1组、C1组和D1组,并且保证四组猫咪的平均年龄差处于最小。每组猫咪中有一半的病情严重,出现精神沉郁、厌食、体温升高、咳嗽、打喷嚏、流泪,眼睛和鼻部有脓性分泌物,剩余一半为咳嗽,流泪,打喷嚏的轻微症状。
应用例1
将本发明实施例1的赖氨酸膏掺入A1组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表2;以及猫咪持续食用一周、两周、三周及四周的病情治愈情况及复发率,具体结果见表3所示。
应用例2
将本发明实施例3的赖氨酸膏掺入B1组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表2;以及猫咪持续食用一周、两周、三周及四周的病情治愈情况及复发率,具体结果见表3所示。
应用对比例1
将对比例1的赖氨酸膏掺入C1组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表2;以及猫咪持续食用一周、两周、三周及四周的病情治愈情况及复发率,具体结果见表3所示。
应用对比例2
将对比例2的赖氨酸膏掺入D1组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表2。
表2 A1组、B1组、C1和D1组猫咪的食用量
表3 A1组、B1组和C1组猫咪的治愈率及复发率
其中,同组猫咪各周的食用量基本一致,因此表2的食用量代表各组四周的平均情况。
由表2可知,本发明的赖氨酸膏对猫咪的适口性较好,喂食猫咪后全部被食用完。由表3可知,猫咪食用本发明的赖氨酸膏后,可以对猫鼻支起到较好的治疗和预防作用。由C1组猫咪的测试结果表明,缺失甘氨酸得到的赖氨酸膏对猫咪的适口性较差,猫咪的喜好性下降,导致食用量下降,并且对猫鼻支的治疗和预防效果均有所下降。
选取80只健康的猫咪,猫咪的品种不限定,均分为A2组、B2组、C2组、D2组和E2组,并且保证五组猫咪的平均年龄差处于最小。
应用例3
将本发明实施例1的赖氨酸膏掺入A2组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表4所示;以及猫咪持续食用一周、两周、三周及四周的发病率,具体结果见表5所示。
应用例4
将本发明实施例3的赖氨酸膏掺入B2组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表4所示;以及猫咪持续食用一周、两周、三周及四周的发病率,具体结果见表5所示。
应用对比例3
将对比例1的赖氨酸膏掺入C2组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表4所示;以及猫咪持续食用一周、两周、三周及四周的发病率,具体结果见表5所示。
应用对比例4
将对比例2的赖氨酸膏掺入D2组猫咪的日常饮食中,每日两次,体重≤2kg,每次0.5-1g;体重≥2kg,每次1-2g,观察猫咪的食用量,具体结果见表4所示;以及猫咪持续食用一周、两周、三周及四周的发病率,具体结果见表5所示。
空白对照组
E2组猫咪不喂食任何赖氨酸膏,观察猫咪一周、两周、三周及四周的发病率,具体结果见表5所示。
表4 A2组、B2组、C2和D2组猫咪的食用量
表5 A2组、B2组、C2组和E2组猫咪的发病率
其中,同组猫咪各周的食用量基本一致,因此表4的食用量代表各组四周的平均情况。
由表4可知,本发明的赖氨酸膏对猫咪的适口性较好,由表5可知,本发明的赖氨酸膏对猫鼻支起到很好的预防作用。由C2组猫咪的测试结果表明,缺失甘氨酸得到的赖氨酸膏对猫咪的适口性较差,猫咪的喜好性下降,导致食用量下降,并且对猫鼻支的预防效果均有所下降。
上述具体实施例仅仅是对本发明的解释,其并不是对本发明的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (6)
1.一种赖氨酸膏,其特征在于,其由包括如下重量份的原料配制而成:明胶1-5份、羟甲基纤维素钠10-20份、蔗糖90-110份、牛磺酸1-10份、全脂牛奶粉25-40份、水解鱼蛋白粉20-40份、骨胶20-40份、维生素1.25-5.95份、甜味剂70-90份、鸡水解膏60-130份、动物油100-120份、L-赖氨酸盐酸盐250-280份和水220-230份。
2.根据权利要求1所述的赖氨酸膏,其特征在于,其由包括如下重量份的原料配制而成:明胶2-4份、羟甲基纤维素钠13-17份、蔗糖95-105份、全脂牛奶粉30-35份、牛磺酸3-8份、水解鱼蛋白粉25-35份、骨胶25-35份、维生素2.41-4.56份、甜味剂75-85份、鸡水解膏90-110份、动物油105-115份、L-赖氨酸盐酸盐260-270份和水221-227份。
3.根据权利要求1所述的赖氨酸膏,其特征在于:所述维生素包括维生素E 1-5份、维生素A 0.1-0.5份、维生素B1 0.05-0.15份、维生素B2 0.05-0.15份和维生素B6 0.05-0.15份。
4.根据权利要求1所述的赖氨酸膏,其特征在于:所述动物油包括鸡油和鱼油。
5.根据权利要求1所述的赖氨酸膏,其特征在于:所述甜味剂包括甜菊糖苷、海藻糖、甘氨酸、L-丙氨酸、丝氨酸中的一种或多种。
6.一种权利要求1-5任一项所述的赖氨酸膏在猫咪营养摄取中的应用,其特征在于:将所述赖氨酸膏掺入猫咪日常饮食中,或直接喂食猫咪,为猫咪补充赖氨酸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910903966.9A CN110521872A (zh) | 2019-09-20 | 2019-09-20 | 一种赖氨酸膏及其在猫咪营养摄取中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910903966.9A CN110521872A (zh) | 2019-09-20 | 2019-09-20 | 一种赖氨酸膏及其在猫咪营养摄取中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110521872A true CN110521872A (zh) | 2019-12-03 |
Family
ID=68669801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910903966.9A Pending CN110521872A (zh) | 2019-09-20 | 2019-09-20 | 一种赖氨酸膏及其在猫咪营养摄取中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110521872A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111493220A (zh) * | 2020-04-22 | 2020-08-07 | 深圳市红瑞生物科技有限公司 | 一种用于犬猫的催乳膏 |
CN112704154A (zh) * | 2020-12-24 | 2021-04-27 | 中国人民解放军66399部队 | 一种用于治疗宠物猫疱疹病毒的营养膏 |
CN112715759A (zh) * | 2020-12-24 | 2021-04-30 | 上海信元宠物食品有限公司 | 一种防结块小颗粒宠物营养补充剂及制作方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107494963A (zh) * | 2017-09-20 | 2017-12-22 | 深圳市红瑞生物科技有限公司 | 宠物钙膏及其制备方法 |
CN109527251A (zh) * | 2018-12-26 | 2019-03-29 | 江苏雅博动物健康科技有限责任公司 | 宠物用软糖及其制备方法 |
CN109619308A (zh) * | 2018-12-26 | 2019-04-16 | 江苏雅博动物健康科技有限责任公司 | 一种用于提高猫咪免疫力来预防猫鼻之的营养膏配方及其制备方法 |
CN109770072A (zh) * | 2018-02-09 | 2019-05-21 | 上海信元动物药品有限公司 | 一种宠物用多色复合型功能软膏及其软膏管 |
-
2019
- 2019-09-20 CN CN201910903966.9A patent/CN110521872A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107494963A (zh) * | 2017-09-20 | 2017-12-22 | 深圳市红瑞生物科技有限公司 | 宠物钙膏及其制备方法 |
CN109770072A (zh) * | 2018-02-09 | 2019-05-21 | 上海信元动物药品有限公司 | 一种宠物用多色复合型功能软膏及其软膏管 |
CN109527251A (zh) * | 2018-12-26 | 2019-03-29 | 江苏雅博动物健康科技有限责任公司 | 宠物用软糖及其制备方法 |
CN109619308A (zh) * | 2018-12-26 | 2019-04-16 | 江苏雅博动物健康科技有限责任公司 | 一种用于提高猫咪免疫力来预防猫鼻之的营养膏配方及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111493220A (zh) * | 2020-04-22 | 2020-08-07 | 深圳市红瑞生物科技有限公司 | 一种用于犬猫的催乳膏 |
CN112704154A (zh) * | 2020-12-24 | 2021-04-27 | 中国人民解放军66399部队 | 一种用于治疗宠物猫疱疹病毒的营养膏 |
CN112715759A (zh) * | 2020-12-24 | 2021-04-30 | 上海信元宠物食品有限公司 | 一种防结块小颗粒宠物营养补充剂及制作方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103315299B (zh) | 一种具有增强免疫力和记忆力功能的保健食品 | |
Gutierrez et al. | Nutritive evaluation of hen eggs | |
KR101361379B1 (ko) | 영양 조성물 | |
CN110521872A (zh) | 一种赖氨酸膏及其在猫咪营养摄取中的应用 | |
RU2009135260A (ru) | Композиции и способы изменения экспрессии генов | |
Park et al. | Production of iron enriched eggs of laying hens | |
EP1593312A1 (en) | Antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine | |
TW201039759A (en) | Reduction of risk of obesity | |
Rabie et al. | Influence of some honey bee products and a growth promoter supplementation on productive and physiological performance of broiler chickens | |
CN104957405A (zh) | 一种无氧化锌的教槽料 | |
Rafiee-Tari et al. | Effect of milk protein composition and amount of β-casein on growth performance, gut hormones, and inflammatory cytokines in an in vivo piglet model | |
da Camara Boueri et al. | Body composition in male rats subjected to early weaning and treated with diet containing flour or flaxseed oil after 21 days until 60 days | |
JP6538043B2 (ja) | 腎機能を向上させるための方法及び組成物 | |
JP2012509669A (ja) | 食物摂取量を変化させ、栄養素消化率を改変し、糞便の質および/または排便回数を変化させるための方法 | |
渡辺武 et al. | Effect of dietary histidine or histamine on growth and development of stomach erosion in rainbow trout. | |
Russ et al. | Post-weaning effects of milk and milk components on the intestinal mucosa in inflammation | |
Sadovoy et al. | Cooked sausage enriched with essential nutrients for the gastrointestinal diet | |
CN104304174A (zh) | 一种富维生素a、富维生素b2鸡蛋的生产方法 | |
CN105580983A (zh) | 一种低胆固醇、富epa鸡蛋的生产方法 | |
Pandya et al. | Overview of functionality of goat and sheep milk | |
JP2005080533A (ja) | 生活習慣病予防改善効果を有するタンパク質食品素材 | |
JP5839815B2 (ja) | 栄養強化鶏卵及びその製造方法 | |
JP2010528651A (ja) | 家禽の体重増量を向上させるための手段および方法 | |
ES2260500T3 (es) | Productos alimenticios ricos en mentionina modificados y procesos para su fabricacion. | |
Kathuria et al. | Animal based bioactives for health and wellness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191203 |